verdiperstat

News

Four more drugs in keenly watched ALS trial miss the mark

ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.

News

Bad news for Biohaven as verdiperstat flunks first phase 3 t...

Biohaven's key pipeline drug verdiperstat has failed to have any therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its lead indication – but

News

Google adds insulin resistance tracker to wearables

In a first for consumer wearables, Google has introduced a feature on Pixel Watch and Fitbit Air devices that it says can monitor insulin resistance.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks